Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCT1002
- Development stage
- Preclinical
- Lead developer
- OncoTherics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intraperitoneal
01
Overview
OCT1002 (uHAP 2) is a next-generation, non-cytotoxic prodrug developed by OncoTherics. It is designed as an ultrasound-activated and hypoxia-activated prodrug (uHAP) that selectively converts into a potent Topoisomerase II (TOPO 2) inhibitor within the hypoxic regions of tumors. This dual-activation mechanism, utilizing both hypoxia and ultrasound, is intended to enhance therapeutic precision and reduce systemic toxicity compared to its predecessor, uHAP 1 (OCT1004). OCT1002 is being developed for the treatment of prostate cancer and has potential for a broad range of other cancers due to its tumor-agnostic mechanism. It is currently in late preclinical development, with Phase 1 clinical trial planning underway.
- Other names
- uHAP 2uHAP2uHAP-2
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on OCT1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCT1002.